Results 61 to 70 of about 15,585 (162)
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT Intraoperatively, in a patient with a history of macroadenoma, the cavernous segment of the internal carotid artery was injured. CTA revealed a dissecting pseudoaneurysm at the carotid bifurcation. This case illustrates a fulminant form of DIPH occurring within days of FD deployment.
Feyz Ebrahimnia +6 more
wiley +1 more source
mBioInfections with multidrug-resistant bacteria pose a major healthcare problem which urges the need for novel treatment options. Besides its potent antiplatelet properties, ticagrelor has antibacterial activity against Gram-positive bacteria, including ...
Kirsten Leeten +22 more
doaj +1 more source
Cardiovascular Diabetology, 2019 Background Microvascular blood flow (MBF) impairment in patients with lower extremity arterial disease (LEAD) is associated with more severe major adverse limb events (MALE).
Robert S. Rosenson +5 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao +8 more
wiley +1 more source
Indian Heart Journal, 2019 Objective: We aimed to assess the efficacy and safety of ticagrelor compared to clopidogrel in Asian patients with acute coronary syndrome (ACS) in real-world practice.
Akhmetzhan Maratovich Galimzhanov +1 more
doaj +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.Abstract Ischemic stroke remains a leading cause of death and disability worldwide, and bleeding (particularly intracranial hemorrhage) continues to limit conventional antithrombotic therapy in secondary prevention, even with direct oral anticoagulants.
Federica Ferrari, Roberto Federico Villa
wiley +1 more source
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.ABSTRACT Purpose Nursing home (NH) residents are at high risk for major bleeding and are frequently exposed to complex medication regimens that may increase the likelihood of clinically important drug–drug interactions (DDIs). However, DDI evidence from community‐dwelling populations may not generalize to NH residents, and real‐world signals involving ...
Adam M. D'Amico +9 more
wiley +1 more source
PLoS ONE, 2018 Ticagrelor, a P2Y12 antagonist, is approved for prevention of thromboembolic events. MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The total plasma exposure of ticagrelor and TAM in patients are roughly 0.5-
Ann-Sofie Sandinge +3 more
doaj +1 more source
Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 499-506, August 2026.In patients with atherothrombotic disease on antithrombotic therapy, P‐CABs demonstrated a significantly superior protective effect against clinically significant upper GI haemorrhage compared to PPIs (aHR 0.22; p = 0.016). This real‐world study highlights P‐CABs as a more potent gastroprotective strategy for high‐risk populations requiring intensive ...
Min Joo Yoon +6 more
wiley +1 more source
Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.ABSTRACT The 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration‐dependent muscle toxicity, at worst rhabdomyolysis.
Ronja Levomäki +3 more
wiley +1 more source